Trinity Biotech plc, a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, announced it has received an order for 9 million units of its flagship HIV screening product, TrinScreen HIV. This significant order marks a pivotal moment in the recovery and strengthening of the global health market for HIV testing, following disruptions earlier this year due to changes affecting international aid funding structures. In addition, the Company provided a trading update for its most recent financial quarters.

The order reflects a renewed commitment from global health organisations to support HIV screening efforts, particularly in regions most affected by the disease. Trinity Biotech’s TrinScreen HIV test is a WHO-prequalified, rapid diagnostic test designed for high-volume screening programs, offering reliable results and ease of use in diverse clinical settings.

Trinity Biotech will produce the tests through its recently WHO-approved outsourced manufacturing process, which allows for efficient and cost-effective scalability. The company anticipates fulfilling the order during the fourth quarter of 2025 and the first quarter of 2026, as it fine-tunes its manufacturing and supply chain to accommodate this significant rise in demand.

This order is expected to positively impact Trinity Biotech’s revenue and profitability outlook and underscores the Company’s strategic positioning in the global infectious disease diagnostics market.